Chemclin Diagnostics Co. Ltd. A (SHG:688468) — Stock Price
Chemclin Diagnostics Co. Ltd. A (SHG:688468) is currently trading at CN¥6.58 CNY, up 0.61% today. Over the past 52 weeks, shares have ranged between CN¥5.55 and CN¥8.40. This page tracks Chemclin Diagnostics Co. Ltd. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Chemclin Diagnostics Co. Ltd. A (688468) market capitalisation.
Chemclin Diagnostics Co. Ltd. A (688468) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Chemclin Diagnostics Co. Ltd. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Chemclin Diagnostics Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
Chemclin Diagnostics Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥332.68 Million | CN¥436.29 Million | CN¥445.34 Million | CN¥465.27 Million | CN¥470.77 Million |
| Cost of Revenue | CN¥111.52 Million | CN¥113.12 Million | CN¥110.56 Million | CN¥121.11 Million | CN¥119.84 Million |
| Gross Profit | CN¥221.16 Million | CN¥323.17 Million | CN¥334.78 Million | CN¥344.16 Million | CN¥350.94 Million |
| Research & Development | CN¥73.31 Million | CN¥75.82 Million | CN¥65.77 Million | CN¥68.89 Million | CN¥67.32 Million |
| SG&A | CN¥29.15 Million | CN¥51.40 Million | CN¥38.86 Million | CN¥39.01 Million | CN¥37.35 Million |
| Total Operating Expenses | CN¥282.36 Million | CN¥188.43 Million | CN¥168.50 Million | CN¥173.87 Million | CN¥188.36 Million |
| Operating Income | CN¥50.32 Million | CN¥134.74 Million | CN¥166.29 Million | CN¥170.29 Million | CN¥162.58 Million |
| EBITDA | CN¥50.32 Million | CN¥189.30 Million | CN¥203.90 Million | CN¥217.97 Million | CN¥205.76 Million |
| EBIT | — | CN¥143.24 Million | CN¥166.74 Million | CN¥177.88 Million | CN¥162.92 Million |
| Interest Expense | CN¥6.41 Million | CN¥5.33 Million | CN¥618.99K | CN¥601.99K | CN¥789.36K |
| Income Before Tax | CN¥50.41 Million | CN¥137.92 Million | CN¥166.12 Million | CN¥177.37 Million | CN¥162.19 Million |
| Income Tax Expense | — | CN¥10.84 Million | CN¥18.75 Million | CN¥24.74 Million | CN¥19.43 Million |
| Net Income | CN¥44.41 Million | CN¥127.07 Million | CN¥147.37 Million | CN¥152.63 Million | CN¥142.76 Million |
Chemclin Diagnostics Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Chemclin Diagnostics Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥1.76 Billion | CN¥1.83 Billion | CN¥1.82 Billion | CN¥1.59 Billion | CN¥1.43 Billion |
| Total Current Assets | CN¥761.59 Million | CN¥1.07 Billion | CN¥1.10 Billion | CN¥1.17 Billion | CN¥1.09 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥301.22 Million | CN¥509.00 Million | CN¥470.00 Million | CN¥643.00 Million | CN¥613.00 Million |
| Net Receivables | CN¥12.93 Million | CN¥24.18 Million | CN¥31.77 Million | CN¥37.01 Million | CN¥38.34 Million |
| Inventory | CN¥110.05 Million | CN¥109.26 Million | CN¥110.61 Million | CN¥112.56 Million | CN¥122.36 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | CN¥153.76 Million | CN¥153.76 Million | CN¥153.76 Million | CN¥153.76 Million | CN¥153.76 Million |
| Total Liabilities | CN¥350.05 Million | CN¥415.85 Million | CN¥431.76 Million | CN¥210.59 Million | CN¥152.23 Million |
| Total Current Liabilities | CN¥159.54 Million | CN¥183.35 Million | CN¥194.13 Million | CN¥197.25 Million | CN¥121.56 Million |
| Long-term Debt | CN¥160.19 Million | CN¥200.19 Million | CN¥196.67 Million | — | — |
| Net Debt | CN¥54.27 Million | CN¥-175.93 Million | CN¥-214.05 Million | CN¥-329.67 Million | CN¥-287.03 Million |
| Total Stockholder Equity | CN¥1.41 Billion | CN¥1.42 Billion | CN¥1.39 Billion | CN¥1.38 Billion | CN¥1.28 Billion |
| Retained Earnings | CN¥440.13 Million | CN¥445.54 Million | CN¥368.99 Million | CN¥374.43 Million | CN¥305.46 Million |
Chemclin Diagnostics Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Chemclin Diagnostics Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥93.90 Million | CN¥167.95 Million | CN¥173.05 Million | CN¥244.56 Million | CN¥188.86 Million |
| Capital Expenditures | CN¥69.88 Million | CN¥107.49 Million | CN¥301.37 Million | CN¥125.28 Million | CN¥72.55 Million |
| Free Cash Flow | CN¥24.01 Million | CN¥60.46 Million | CN¥-128.32 Million | CN¥119.28 Million | CN¥116.31 Million |
| Investing Cash Flow | — | CN¥-134.06 Million | CN¥-307.68 Million | CN¥-114.50 Million | CN¥-310.54 Million |
| Financing Cash Flow | — | CN¥-87.93 Million | CN¥44.01 Million | CN¥-79.95 Million | CN¥242.00 Million |
| Dividends Paid | CN¥54.79 Million | CN¥53.28 Million | CN¥139.15 Million | CN¥68.17 Million | — |
| Stock-Based Compensation | — | — | — | CN¥17.45 Million | — |
| Depreciation | CN¥56.50 Million | CN¥53.70 Million | CN¥49.29 Million | CN¥51.21 Million | CN¥52.98 Million |
| Change in Cash | CN¥-90.65 Million | CN¥-53.97 Million | CN¥-90.54 Million | CN¥50.51 Million | CN¥120.22 Million |
Chemclin Diagnostics Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track Chemclin Diagnostics Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2023 | 0.09 | — | — |
| Dec 31, 2022 | 0.09 | — | — |
| Sep 30, 2022 | 0.12 | — | — |
| Jun 30, 2022 | 0.08 | — | — |
| Mar 31, 2022 | 0.10 | — | — |
| Dec 31, 2021 | 0.09 | — | — |
| Sep 30, 2021 | 0.09 | — | — |
| Jun 30, 2021 | 0.08 | — | — |